Robert Schreiber, PhD

Research Program Tumor Immunology
Robert Schreiber

Researcher Background

Primary Academic Title

Andrew M. and Jane M. Bursky Distinguished Professor of Immunobiology, WashU Medicine

Training

  • 1973: Postdoctoral Fellow, Medicine and Biochemistry, State University of New York, Buffalo, NY
  • 1973 - 1976: Postdoctoral Fellow, Molecular Immunology, Scripps Research Institute, La Jolla, CA

Education

  • 1973: PhD, Biochemistry and Immunology, State University of New York, Buffalo, NY

Research & Selected Publications

Research Interest

Biology and signaling of cytokines with special emphasis on IFN-gamma and TNF; role of IFN-gamma in tumor immunity

Research Publications

Cancer Neoantigen Vaccines Emerge Efficacious.
Authors:

Sultan H, Schreiber RD

Journal & Year:

Annu Rev Med • 2026

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Authors:

Zhang X, Goedegebuure SP, Chen MY, one or more additional authors omitted Schreiber RD, Gillanders WE

Journal & Year:

Genome Med • 2024

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.
Authors:

Sultan H, Takeuchi Y, Ward JP, one or more additional authors omitted Schreiber RD

Journal & Year:

Nature • 2024

Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry.
Authors:

Meng W, Takeuchi Y, Ward JP, one or more additional authors omitted Schreiber RD

Journal & Year:

Cancer Immunol Res • 2024

IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.
Authors:

Moynihan KD, Kumar MP, Sultan H, one or more additional authors omitted Schreiber RD, one or more additional authors omitted Djuretic IM

Journal & Year:

Cancer Discov • 2024

TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy.
Authors:

Di Luccia B, Molgora M, Khantakova D, one or more additional authors omitted Schreiber RD, one or more additional authors omitted Colonna M

Journal & Year:

Sci Immunol • 2024

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response.
Authors:

Thisted T, Smith FD, Mukherjee A, one or more additional authors omitted Schreiber RD, van der Horst EH

Journal & Year:

Nat Commun • 2024